A Phase 1 Randomized, Placebo-controlled, Single and Multiple Ascending Dose Study of the Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 30 Sep 2017
At a glance
- Drugs AG 10 (Primary)
- Indications Amyloidosis
- Focus Adverse reactions; First in man
- Sponsors Eidos Therapeutics
- 28 Sep 2017 According to an Eidos Therapeutics media release, dosing of the first healthy adult cohort has commenced.
- 22 Sep 2017 Status changed from planning to recruiting.
- 08 May 2017 According to an BridgeBio Pharma media release, this study is expected to initiate in the second half of 2017.